Maybe you searched Ro vs Medvi, or Medvi vs Ro. Either way, you’re comparing two of the most-searched GLP-1 telehealth providers for 2026. Both deliver weight-loss medication to your home. The prices diverge. MEDVi charges $299 flat, all-in. Ro costs $39 the first month, then $74 to $149 per month depending on your plan, plus the medication.
That gap inverts the moment insurance enters the picture. Ro gives hands-on support to navigate coverage and prior authorization, and an approved member can drop to a $25 to $50 co-pay. MEDVi does not accept insurance at all. If you want a broader view before committing, our roundup of the best online tirzepatide providers maps the full field. This article stays focused on the two-provider comparison.
Cash-pay readers will usually want MEDVi, insured readers will usually want Ro, and four specific questions settle it. We walk through year one cost math, the February 2026 FDA enforcement context, Ro’s December 2025 peer-reviewed outcomes paper, and what the Wegovy pill (FDA-approved December 2025) changes for needle-phobic buyers.
We have tracked both providers through the 2026 compounding crackdown, the MEDVi warning letter, and the OpenLoop breach. No unconditional winner. Just the math and the fit.
How Ro and Medvi Differ at a Glance
Ro is a membership-plus-medication model built around insurance optimization. MEDVi is a flat-fee all-inclusive model built around cash-pay access. The rest of the article is detail behind that sentence.
| Feature | Ro Body | MEDVi |
|---|---|---|
| Pricing model | Ro Body membership ($74 to $149/mo after the $39 first month) + medication | Flat all-inclusive |
| Monthly cost, semaglutide, maintenance | ~$448 cash, $25-$50 co-pay with insurance | $299 cash, no insurance route |
| Compounded GLP-1s | No (FDA-approved only as of 2026) | Yes (injectable and oral tablets) |
| FDA-approved medications | Wegovy pill and pen, Foundayo pill, Zepbound KwikPen and pen, Ozempic | Branded via optional $99 membership route |
| Insurance handling | Insurance Concierge, full PA support | Does not accept insurance |
| Onboarding speed | Cash medication can arrive in less than a week; insurance checks take about 2-3 weeks | 24-48 hour review, medication in 3-5 days |
| Lab work required | Yes | No (optional) |
| Video visit required | Yes, up to 2 weeks to schedule | No (async) |
| Pharmacy partner | LillyDirect, NovoCare, varied | Belmar Pharma Solutions (503A/503B, 39 years) |
| Published outcomes study | 16.6% avg weight loss at 68 weeks (n=655, Obesity, Dec 2025) | None published |
| Trustpilot rating | 3.9/5 as of September 17, 2026 | 4.4-4.5/5 from 11,400+ reviews |
Insurance drives most of the difference. The KFF 2025 Employer Health Benefits Survey found that 43% of large employer plans (5,000+ employees) cover GLP-1s for weight loss, and nearly all of them require prior authorization. If you have coverage, Ro’s membership costs $74 to $149 per month after the first month, and your medication might be only a copay. Without coverage, MEDVi ends up roughly $1,500 to $2,300 cheaper per year.
Most comparison articles miss the 2026 update: Ro no longer offers compounded GLP-1s. Ro pivoted to FDA-approved branded medications only, including the Wegovy pill (FDA-approved December 2025, launched January 2026). MEDVi is the compounded route. Ro is the branded route.
Year-1 projections come next.
Pricing and the Real Cost Math
Both providers bill every 28 days, not monthly. That means 13 charges per calendar year, not 12, and advertised monthly prices understate the real annual cost by roughly 8%.
The baseline numbers: MEDVi compounded semaglutide is $179 the first month then $299 per cycle, flat across titration. MEDVi compounded tirzepatide is $349 flat. Ro Body membership is $39 the first month then $149 ongoing (or $74 monthly on annual prepay), with medication layered on top. Wegovy pen is $199 promo the first month then $349 ongoing. Zepbound starts at $299 at 2.5 mg, climbs to $399 at 5 mg, and hits $449 at 7.5 to 15 mg; a missed 45-day check-in can escalate Zepbound to $499 or $699. The Wegovy pill (oral semaglutide) is $149 starter and $199 to $299 ongoing through Novo self-pay.
Year-1 math, side by side:
| Scenario | Year 1 Total | Notes |
|---|---|---|
| MEDVi semaglutide (12 cycles) | $3,468 | $179 intro + $299 x 11 |
| MEDVi semaglutide (28-day billing, 13 cycles) | ~$3,767 | Real annual |
| MEDVi tirzepatide | ~$4,170 | $349 x 12 approx |
| Ro Wegovy pen, cash pay | ~$5,566 | Monthly plan: $39 + $149 x 11 membership, plus $199 x 2 + $349 x 10 medication. Less on a prepaid plan |
| Ro Wegovy pill, cash pay | ~$5,016 | Monthly plan: $1,678 membership, plus $149 + $199 + $299 x 10 medication |
| Ro Zepbound KwikPen, 15 mg maintenance | ~$7,066 | Monthly plan: $1,678 membership, plus $449 x 12 medication |
| Ro Wegovy pen with insurance co-pay | ~$1,978 to $2,278 | Monthly plan: $1,678 membership, plus $25 to $50 co-pay x 12 |
There’s also the hidden cost of waiting for prior auth. Ro’s PA process usually takes 2 to 3 weeks. During that time, your membership keeps charging based on the plan you picked, and medication is billed separately. Build that into your budget.
The dose-titration trap compounds it further. Zepbound at 2.5 mg is $299; at 7.5 to 15 mg it is $449 to $499+. Most patients titrate to maintenance within six months, so year 2 almost always costs more than year 1. MEDVi’s price is flat across every dose, so savings compound for patients heading toward maintenance.
Quick comparison: MEDVi is roughly $1,500 to $2,300 cheaper per year for cash-pay patients. Ro wins only when insurance pays the medication, which requires the PA process and the wait cost that comes with it.
Medications: Compounded vs FDA-Approved (and the Wegovy Pill)
The medication each provider prescribes changed meaningfully in 2026. Most comparison articles still describe a 2024 catalog. What is available right now looks different.
Ro only offers FDA-approved medications. These include the Wegovy pill (daily oral semaglutide), the Wegovy pen (weekly injectable semaglutide), Foundayo (a daily orforglipron tablet from Eli Lilly), Zepbound (tirzepatide via the KwikPen or an autoinjector pen), and Ozempic (off-label for weight loss). There are no compounded GLP-1s. Many competitor reviews miss this 2026 update. Ro stays in the branded lane.
MEDVi offers a wider catalog. Compounded semaglutide injection runs $299 monthly (flat). Compounded tirzepatide injection is $349 monthly. Oral semaglutide tablets are $249. Oral tirzepatide tablets are $279. A separate $99 monthly membership unlocks a brand-name route for Wegovy or Zepbound at manufacturer self-pay pricing, which is MEDVi’s under-reported path for patients who want FDA-approved medication without Ro’s higher membership.
The oral tirzepatide tablets deserve a red flag. There is no published human absorption data. Tirzepatide is a roughly 4,813-dalton peptide, and digestive enzymes break peptides down before systemic absorption. For reference, Rybelsus (FDA-approved oral semaglutide for diabetes) achieves only about 1% oral bioavailability using a specialized SNAC absorption enhancer under strict fasting conditions. Compounded oral tirzepatide tablets use no equivalent technology. A November 2025 class-action complaint against OpenLoop Health and Triad Rx (MEDVi’s clinical partners) alleges these tablets cannot produce a therapeutic effect.
The Wegovy pill is a daily semaglutide tablet. Ro offers it as a cash-pay medication. Ro lists Eli Lilly’s FDA-approved orforglipron tablet as Foundayo. Both give you an oral GLP-1 option instead of an injection, though medication availability, pricing, and eligibility can vary.
Best for needle-free efficacy: Ro Wegovy pill. Skip MEDVi oral tirzepatide until absorption data exists.
Insurance, Prior Auth, and the Membership-Fee Trap
Ro’s membership is always a separate charge from medication. You pay $39 for the first month, and Ro refunds that $39 if you are not eligible for GLP-1s. After that, the fee depends on the plan: $74 per month on the 12-month plan, $89 on the 6-month plan, $99 on the 3-month plan, or $149 on the monthly plan. Ro offers hands-on support to navigate coverage for your medication.
The coverage pool is finite. Per the KFF 2025 Employer Health Benefits Survey, 43% of large employer plans (5,000+ employees) cover GLP-1s for weight loss, and virtually all require prior authorization. Roughly half of covered patients face co-pays of $50 or less. A real Ro patient example: Michelle B. (October 2025) paid $25 monthly for Zepbound after Ro’s Insurance Concierge secured her coverage. Total monthly cost: $174.
The other 57% of large employer plans do not cover weight-loss GLP-1s. Smaller employers and individual marketplace plans cover at even lower rates. If you are in that majority, Ro’s Insurance Concierge cannot help you. You will pay Ro’s full cash price ($448 to $498 monthly at maintenance doses on the monthly plan) or switch to MEDVi.
The wait costs you whether you are approved or not. Ro’s PA process typically runs 2 to 3 weeks. Your membership keeps billing based on the plan you chose, and medication is charged separately. Budget for that before you sign up.
Direct recommendation: if you work for an employer with 5,000+ employees, run Ro’s free GLP-1 Coverage Checker before you sign up. If your plan covers weight-loss GLP-1s, pay the membership. If it does not, skip the insurance wait and go MEDVi.
Speed and Onboarding
If you want medication in your hand this week, both can do it on cash pay. Insurance is what slows Ro down.
MEDVi runs async. Online intake form, provider review within 24 to 48 hours (document-based, no video visit required in most cases), prescription issued if you qualify. No upfront lab work. Medication ships within 24 hours of approval and arrives in 3 to 5 days. Typical signup-to-injection timeline: 4 to 6 days. You then get 24/7 provider messaging and dose adjustments at no extra charge.
Ro is structured differently. You complete an online intake, and a licensed provider reviews it and orders lab testing if necessary. If you use insurance, the insurance concierge runs the coverage check and files any prior authorization paperwork, which takes about 2 to 3 weeks, and you pick up the medication at your pharmacy. If you pay cash, Ro ships the medication to your door and your first dose can arrive in less than a week. Ro charges the membership only if you are eligible, and it refunds the $39 first month if you are not.
Ro’s clinical structure (provider review, lab testing if necessary) is a safety feature. The insurance route adds a coverage check of about 2 to 3 weeks. MEDVi’s async model trades safety screening for speed.
The verdict: speed goes to MEDVi by roughly 2 to 3 weeks, or 5 to 9 weeks if Ro pursues insurance.
Safety, FDA Enforcement, and Pharmacy Credentials
The February 2026 FDA warning letter to MEDVi made headlines. Most readers took the wrong lesson from it. Here is what the letter said, and what it did not say.
On February 20, 2026, MEDVi received FDA Warning Letter #721455 for misbranding violations. The letter addressed marketing language: MEDVi’s website suggested MEDVi itself was the compounder (it is not; Belmar Pharma is) and implied FDA approval of compounded products (compounded drugs are not FDA-approved). The letter did not cite manufacturing, safety, or medication quality problems. More than 30 telehealth companies received similar letters in March 2026 in an industry-wide enforcement wave.
Tirzepatide came off the FDA shortage list in December 2024 (enforcement discretion ended March 2025). Semaglutide came off in February 2025 with 503A and 503B deadlines in April and May 2025. As of April 1, 2026, neither drug is on the shortage list or the 503B bulks list. 503A pharmacies retain a narrow safe harbor: no more than 4 essentially-a-copy prescriptions per patient per month with robust documentation. 503B bulk compounding is largely foreclosed.
Belmar Pharma Solutions, MEDVi’s pharmacy partner, was established in 1985 (39 years of operating history). Belmar operates both 503A state-licensed pharmacies and FDA-registered 503B outsourcing facilities across six locations, licensed in 49 states. Ingredients are sourced exclusively from FDA-registered suppliers, batches are independently lab-tested, and cGMP protocols are in place. Even 503B status does not exempt Belmar from the new bulk-compounding restrictions. MEDVi is operating in a tightened regulatory lane, not an illegal one, but supply chain risk is real and worth naming.
MEDVi also outsources clinical care to OpenLoop Health, which disclosed a January 2026 data breach affecting approximately 1.6 million patient records (68,160 confirmed in Texas). MEDVi patients may be among those affected. Ro has no comparable breach on record. If PHI security weighs heavily for you, this tips toward Ro.
Quick comparison: the FDA letter is a reputational signal, not a safety signal. Belmar is credentialed but operating in a shrinking legal lane. The safety differentiator right now is the OpenLoop breach exposure.
Real Outcomes and Support Quality
Only one of these providers has published peer-reviewed outcomes data on its own patients. That asymmetry matters when you are deciding where to spend $3,500 to $5,800 a year.
Ro published a real-world outcomes study in Obesity journal on December 10, 2025. The sample was 655 Ro patients, median age 45.8, 67.9% women, median BMI 32.3. At 68 weeks, average body weight loss was 16.6% (95% CI -17.1 to -16.0). 95.4% of patients lost at least 5% of body weight, 82.0% lost at least 10%, and 32.8% lost at least 20%. No new safety signals. Most common side effects: nausea or vomiting (37.3%) and constipation (15.6%).
MEDVi has no published outcomes study. The marketing relies on Trustpilot testimonials (4.4 to 4.5/5 from 11,400+ reviews, many invited) and ConsumerAffairs (3.6/5 from 1,600 reviews, complaint-skewed). Individual stories exist: Melany lost 31 pounds and reached a size 12/14 for the first time in 15 years; James lost 13 pounds in two months. Testimonials, not data.
Support depth differs. Ro includes coaching, regular check-ins, 1:1 provider messaging, and a multi-service platform (ED, hair, fertility, mental health), though Healthline’s medical review team notes Ro is “lighter on behavioral support than competitors.” MEDVi offers 24/7 unlimited provider messaging, dose adjustments included, and anti-nausea medication if needed. No behavioral coaching.
Cancellation friction is the other asymmetry. MEDVi has documented billing complaints: 28-day billing (13 charges per year, not 12), a 72-hour cancellation notice requirement, post-cancellation charges, a money-back guarantee that requires 5 months of continuous use with a 25% deduction, and a standard refund policy that reads “IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION.” Ro’s cancellation is straightforward, with no comparable complaint pattern on record.
Best for evidence-backed outcomes: Ro. Skip MEDVi if refund terms matter to you.
Who Each One Is Actually For (Including Cortisol and Menopause)
You have probably tried the willpower version of weight loss. If you landed here from our cortisol or perimenopause content, you already know hormonal and stress-driven weight resistance is real. The clinical evidence on GLP-1s in that context is blunt.
The SURMOUNT-1 post-hoc analysis (n=2,542 women), published in Obesity journal 2025, found perimenopausal women on tirzepatide lost 23% of body weight vs 3% on placebo. That is virtually identical to the 26% loss in premenopausal women. Postmenopausal women also lost 23%. Dr. Beverly Tchang at Weill Cornell put it plainly: tirzepatide “works well regardless of a woman’s decade of life.” Mikdachi and Dunsmoor-Su, writing in Current Opinion in Obstetrics and Gynecology (April 2025), called GLP-1 RAs “consistently the most effective pharmacologic for weight loss” in this population.
Ro fits this reader profile:
You have insurance that covers GLP-1 medication for weight loss.
You want FDA-approved medication only, including the Wegovy pill, Wegovy pen, Foundayo, and Zepbound.
You prefer an oral option such as the Wegovy pill or Foundayo.
You value licensed providers, ongoing support, coaching, and lab testing if necessary.
You want hands-on support to navigate coverage, including insurance.
MEDVi fits this reader profile:
– Cash-pay patients with no GLP-1 insurance coverage.
– Buyers who want tirzepatide at the lowest price available ($349 monthly compounded).
– Patients who have bounced from Hers, Noom, or Found and want fast re-entry without video-visit scheduling.
– Patients comfortable with compounded medication from a 503A/503B-credentialed pharmacy.
– Patients who do not need behavioral coaching or labs.
Direct recommendation for the cortisol or perimenopause reader: tirzepatide is the better-evidenced molecule for your situation, and MEDVi is the lowest-friction route to it at $349 monthly if you are cash-pay. If you have employer coverage, Ro Zepbound through insurance is cheaper.
The Bottom Line: A 4-Question Decision Framework
Four questions settle this for almost every reader. Answer them honestly and the right provider falls out.
Question 1: Does your insurance cover GLP-1s for weight loss? If yes, Ro provides hands-on support to navigate coverage and submit prior-authorization paperwork when needed. Run Ro’s free insurance check before you sign up. Insurance pays for medication, not the Ro Body membership, and the two are separate charges. If no, or if you are unsure, go to Question 2.
Question 2: Is FDA-approved medication non-negotiable for you? If yes (you want the Wegovy pill, Foundayo pill, Zepbound KwikPen, Wegovy pen, or Ozempic), then Ro fits. Cash prices depend on the medication and dose. If you are comfortable with compounded semaglutide from a credentialed pharmacy, continue to Question 3.
Question 3: What is your monthly budget? Under $350 all-in: MEDVi compounded semaglutide ($299) is the only fit. $350 to $550: both are viable. MEDVi compounded tirzepatide at $349 is the better molecule. Ro’s Wegovy pill plus membership runs $298 to $448 monthly on the monthly plan, or $223 to $373 on the 12-month prepaid plan, depending on dose. Over $550: Ro Zepbound, or MEDVi’s $99 branded membership route paired with branded self-pay.
Question 4: How fast do you want to start? If you need to start ASAP, in days and not weeks, MEDVi has a 24 to 48 hour review and medication in 3 to 5 days. If you can wait for a proper clinical setup, Ro says a cash-pay medication can arrive in less than a week. With insurance, the insurance check takes about 2 to 3 weeks.
For most cash-pay buyers comparing Ro and MEDVi specifically, MEDVi wins on price and speed. For insured buyers at large employers, Ro wins on total cost and clinical rigor. If you want a broader look at who else competes on compounded tirzepatide pricing and sublingual options before you commit, see our full roundup of the best online tirzepatide providers. For adjacent comparisons, see Ro vs Noom (the behavioral coaching angle) and our broader best GLP-1 program ranking for nine providers scored by situation.
Frequently Asked Questions
A few more questions readers search repeatedly before deciding.
Is Ro or MEDVi cheaper?
For cash-pay buyers, MEDVi semaglutide is $299 flat all-in. Ro charges a separate membership fee and medication cost. The Ro Body membership starts at $39 for the first month, then costs $74 to $149 monthly depending on the plan. Medication prices depend on the drug and dose. For insured patients, Ro’s medication cost depends on coverage and may be just the copay. Insurance never pays the membership fee.
Does Ro offer compounded tirzepatide in 2026?
No. As of 2026, Ro only prescribes FDA-approved medications: the Wegovy pill, Wegovy pen, Foundayo pill, Zepbound KwikPen, and Ozempic off-label. Ro does not offer any compounded GLP-1. Competitor articles claiming otherwise are outdated.
Are MEDVi’s compounded GLP-1s safe?
Compounded medications from licensed pharmacies use the same active molecule as branded drugs but are not FDA-approved for safety, efficacy, or quality. MEDVi’s Belmar pharmacy partner has a 39-year history with 503A/503B licensing and cGMP protocols. The February 2026 FDA warning letter addressed marketing language, not safety. The OpenLoop January 2026 breach did affect potential MEDVi patient records.
Is MEDVi’s oral tirzepatide tablet effective?
No published human absorption data exists. A November 2025 class-action complaint alleges the tablets cannot produce a therapeutic effect because tirzepatide is a peptide that digestive enzymes break down before systemic absorption. For needle-free GLP-1 with real efficacy evidence, Ro offers the Wegovy pill and Foundayo pill.
How long does Ro’s insurance prior authorization take?
Ro says the insurance check takes about 2 to 3 weeks. If you need prior authorization, Ro’s insurance concierge submits the paperwork. The Ro Body membership is a separate charge from medication. The fee depends on the plan: $39 for the first month, then $74 to $149 monthly on the available prepaid or monthly plans. Insurance pays for medication only. It never pays the membership fee.
Can I get Wegovy or Zepbound through MEDVi?
Yes, via MEDVi’s $99 monthly branded membership route. This gives access to brand-name Wegovy and Zepbound at manufacturer self-pay pricing. It is a lower-fee alternative to the Ro Body membership for patients who want FDA-approved medication without Ro’s full platform. The Ro Body membership starts at $39 for the first month and then ranges from $74 to $149 monthly depending on the plan.
Do GLP-1s work for perimenopausal weight gain?
Yes. A SURMOUNT post-hoc analysis of 2,542 women found perimenopausal women on tirzepatide lost 23% of body weight vs 3% on placebo, nearly identical to the 26% loss in premenopausal women. Lead researcher Dr. Beverly Tchang confirmed tirzepatide “works well regardless of a woman’s decade of life.”
What happens to weight after stopping a GLP-1?
Most patients regain weight quickly. The STEP 1 trial extension (semaglutide 2.4 mg) showed participants regained two-thirds of lost weight within one year of stopping. Net result: only -5.6% from baseline at month 120 vs -17.3% at peak. Both Ro and MEDVi assume chronic ongoing treatment; neither offers a specific off-ramping protocol.
Want the wider field? See our Best Tirzepatide Online ranking, Best Semaglutide Online, or our best online GLP-1 program comparison.